Addex adx71149 phase 2 epilepsy study expected to readout data in q2 2024

Cohort 1 is completed , and cohort 2 is 80% recruited ad hoc announcement pursuant to art. 53 lr geneva, switzerland, september 5 , 202 3 - addex therapeutics (six and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the adx71149 (jnj-40411813) phase 2 epilepsy clinical study is progressing well, with cohort 1 completed and 80% of patients recruited into cohort 2.
ADXN Ratings Summary
ADXN Quant Ranking